Biomarkers are essential tools in clinical research and practice. Useful biomarkers must combine good measurability, validated association with biological processes or outcomes, and should support clinical decision making if used in clinical practice. Several types of validated biomarkers have been reported in the context of bone diseases. However, because these biomarkers face certain limitations there is an interest in the identification of novel biomarkers for bone diseases, specifically in those that are tightly linked to the disease pathology leading to increased fracture-risk. MicroRNAs (miRNAs) are the most abundant RNA species to be found in cell-free blood. Encapsulated within microvesicles or bound to proteins, circulating miRNAs are remarkably stable analytes that can be measured using gold-standard technologies such as quantitative polymerase-chain-reaction (qPCR). Nevertheless, the analysis of circulating miRNAs faces several pre-analytical as well as analytical challenges. From a biological view, there is accumulating evidence that miRNAs play essential roles in the regulation of various biological processes including bone homeostasis. Moreover, specific changes in miRNA transcription levels or miRNA secretory levels have been linked to the development and progression of certain bone diseases. Only recently, results from circulating miRNAs analysis in patients with osteopenia, osteoporosis and fragility fractures have been reported. By comparing these findings to studies on circulating miRNAs in cellular senescence and aging or muscle physiology and sarcopenia, several overlaps were observed. This suggests that signatures observed during osteoporosis might not be specific to the pathophysiology in bone, but rather integrate information from several tissue types. Despite these promising first data, more work remains to be done until circulating miRNAs can serve as established and robust diagnostic tools for bone diseases in clinical research, clinical routine and in personalized medicine.
Introduction
Personalized (or also termed precision) medicine is entering clinical research and practice, since the enormous power of novel molecular biological methods has helped to uncover biomarkers, which stratify patients into distinct subgroups with individual needs for treatment. However, many novel biomarkers have not yet been translated into clinical routine (Regierer et al., 2013) . This is due to the fact that frequently, novel markers do not meet the criteria of a biomarker, which is defined by the World Health Organization (WHO) as "any substance, its products, structure or process that can be measured in the body and that influences or predicts the incidence of outcome or disease." (WHO definition of biomarkers, Lassere, 2008) . Others might fulfill the WHO criteria of a biomarker, but are not up to the standards of clinical utility (Morrow and De Lemos, 2007) .
In the field of bone diseases, especially with regard to fracture risk assessment in osteoporosis, validated tools are used in clinical routine such as bone mineral density by Dual-X ray absorptiometry (DXA) and the WHO-FRAX score (Siris et al., 2014) (Johnell et al., 2005; Marshall et al., 1996) (Kanis et al., 2007) . However, both tools still have limitations (Cranney et al., 2007; Silverman and Calderon, 2010) , especially in regard to fracture risk assessment when contributing factors such as diabetic osteopathy are present (Schwartz et al., 2011) . For the prediction of disease progression or monitoring treatment success (in respect to fracture risk) bone turnover markers such as serum procollagen type I N propeptide (s-P1NP) and serum C-terminal telopeptide of type I collagen, (s-CTX) can be used (Bauer et al., 2012) . Both markers are collagen metabolites that reflect the (coordinated) activity of osteoblast and osteoclast formation, i.e. bone formation and bone resorption (Vasikaran et al., 2011) and could detect efficacy of therapy sooner than DXA (Bauer et al., 2012) . However, to date s-CTX and s-P1NP still face specific limitations to become validated in vitro diagnostics including lack of normative reference population databases, inadequate standardization of quality control, sample handling (Bauer et al., 2012) and moderate association with bone strength and fracture risk (Ivaska et al., 2010; Wheater et al., 2013) . Novel, different biomarkers are therefore desirable, which can alone or in combination with existing biomarkers provide a better understanding of bone strength and consequently fracture risk in patients.
In this review we will therefore i) introduce the concept of circulating microRNAs (miRNAs) as minimal-invasive biomarkers, ii) discuss the opportunities and challenges associated with using circulating miRNAs as biomarkers, iii) summarize recently published literature on circulating miRNAs in aging and musculoskeletal diseases as part of frailty, and iv) provide an outlook over the future steps necessary to develop circulating miRNA based biomarkers for use in clinical routine.
microRNAs (miRNAs)
In search of novel biomarkers that reflect the systemic physiological state and will foster our basic understanding as well as clinical disease management, -OMICs-based approaches become more and more important (Erusalimsky et al., 2015) . Especially small non-coding RNAs have gained increased attention as biomarker candidates during the last years (De Guire et al., 2013) . Among them, in particular miRNAs have been found to fulfill important regulatory roles in almost any type of cell or tissue, including bone and muscle (Callis et al., 2007; Lian et al., 2013) , by inhibiting target gene expression. According to miRBase version 21, sequences of 2588 mature human miRNAs have been catalogued so far (Kozomara and Griffiths-Jones, 2014) , which are either characterized by ubiquitous or tissue specific expression (Guo et al., 2014; Liang et al., 2007) . Biogenesis of miRNAs (see Fig. 1 ) either starts from intergenic primary transcripts through processing by the enzyme complex Drosha/Dgcr8 or from intragenic regions through splicing. The resulting short hairpin RNAs (precursor microRNA) undergo cleavage by Dicer and give rise to a short mature miRNAduplex (Winter et al., 2009) , which vary in size between 18 and 24 basepairs. After strand separation, either the 5 0 or 3 0 miRNA becomes selectively incorporated into the miRNA induced silencing complex (miRISC), which it guides to the 3 0 untranslated regions (UTR) of messenger RNA (mRNA) molecules that harbor partially complementary sites (Bartel, 2009) . Binding of miRISC to a mRNA results in post-transcriptional gene silencing either through the inhibition of mRNA translation (Pillai et al., 2005) or mRNA destabilization (Guo et al., 2010) . Interactions between mRNA and miRNA show two important characteristics: i) a single miRNA is commonly capable of binding up to hundred or more distinct mRNA species. ii) 3' UTR regions of most mRNAs contain binding sites for multiple miRNAs. The resulting pleiotropy of interactions and combinatorial/cooperative activity of miRNAs enables the regulation of complex gene expression networks, in a similar fashion to transcription factors (Hobert, 2008) . It is thus believed that miRNAs are an evolutionarily conserved layer of epigenetic regulation of complex processes such as cell growth and differentiation, stress response and coordinated cell death. Although it is assumed that the redundancy in miRNA~mRNA interactions could serve as a buffer against perturbations (Shenoy and Blelloch, 2014) , ensuring the robustness of biological systems, it has been shown that knockdown or overexpression of single miRNAs can significantly alter cellular phenotypes and therefore have strong therapeutic potential (Babar et al., 2012; Elm en et al., 2008; Krzeszinski et al., 2014; Medina et al., 2010) .
Circulating microRNAs
Starting in 2007, initial observations were made that mature miRNAs are released from cellular cytoplasm within extracellular vesicles (EVs, see Fig. 1 ) (Valadi et al., 2007) . To this day, the presence of "circulating microRNAs" was verified in 12 different biofluids . Meanwhile circulating miRNAs have not only be found encapsulated within extracellular vesicles but also within vesicles formed by high-density lipoproteins (HDL) (Vickers et al., 2011) as well as in association with RNA binding proteins such as nucleophosmin or proteins of the Argonaute (Ago) family (Arroyo et al., 2011 ) (see Fig. 1 ). The vesicular encapsulation or protein association of miRNAs accounts for their remarkable stability in biofluids (Turchinovich et al., 2012) . Although the majority of plasma derived miRNAs was shown to be bound to protein, (Arroyo et al., 2011) , the mechanisms by which these vesicle efree miRNAs are released or taken up by cells are still unclear. In contrast, the secretion of miRNAs that are encapsulated (1) microRNAs are derived from intergenic or intronic genomic regions. In case of intergenic miRNAs, the initial primary transcripts (not shown) are cleaved by Drosha/Dgcr8 to form precursor miRNAs (Pre-miRNA). Alternatively, splicing of intronic miRNAs can give rise to pre-miRNAs. (2) Pre-miRNAs are shuttled via Exportin-5 into the cytoplasm where cleavage by Dicer into double-stranded miRNA duplexes occurs. (3) Single-stranded miRNAs guide the RISC protein complex to target mRNAs resulting in translational repression. (4) mature miRNAs as well as Pre-miRNAs are sorted into ectosomes, which bud from the cell membrane. (5) Intracellularly, multivesicular bodies (MVBs) are formed, which contain exosomes of 50e100 nm size. MVBs fuse with the cell membrane to release miRNA loaded exosomes from the Donor Cell into the supernatant. (6) Lipoprotein or Ago-2 associated miRNAs are present in cell-free liquids. (7) Protein-bound or encapsulated miRNAs are transported with the blood stream. (8) Uptake of extracellular RNA by an Acceptor Cell that is different from the Donor Cell, and potentially located in a different tissue.
in vesicles is well-known and has been shown to be non-random and energy dependent .
Based on their biogenesis, two types of extracellular vesicles can be distinguished: (i) Microvesicles which directly bleb from the plasma membrane (Trams et al., 1981) of viable (termed ectosomes) or apoptotic cells (termed apoptotic bodies) and (ii) exosomes formed by inward budding of late endosomes (Pan and Johnstone, 1983) . These latter vesicle -filled endosomes are called multivesicular bodies (MVB). Upon fusion of MVBs with the plasma membrane, vesicles are released as so called exosomes (Weilner et al., 2013) .
Extracellular vesicles contain not only miRNAs but also other non-coding RNAs, mRNAs, proteins, and DNA . Out of the non-coding RNA fraction contained in extracellular plasma vesicles, about 75% are miRNAs (Huang et al., 2013) . Interestingly, it could be shown that the composition of vesicular miRNAs does not reflect the repertoire of miRNAs within the donor cell (Pigati et al., 2010) and that miRNA secretion levels can alter under different physiological as well as pathological conditions (Weilner et al., 2013) , thereby stressing the notion that the incorporation and secretion of miRNAs is a highly regulated process. Although the underlying mechanisms that regulate the incorporation of RNAs into vesicles is still not completely understood, evidence suggests that at least five different factors may impact the vesicular miRNA content. (i) Expression levels of neutral sphingomyelinase 2 (nSMase2), a protein playing a crucial role in ceramide synthesis, correlate with the amount of secreted extravesicular miRNAs (Kosaka et al., 2010) . Interestingly, it has been shown that high levels of nSMase2 result in increased levels of extravesicular miRNAs but reduce the amount of secreted microRNAs encapsulated within HDL particles (Vickers et al., 2011) (ii) Sumoylated heterogeneous nuclear ribonucleoproteins (hnRNPs) load miRNAs into extracellular vesicles dependent on a specific nucleotide sequence at their 3 0 end. For example hnRNPA2B1 preferentially packs miRNAs containing a GGAG motif into vesicles (Villarroya-Beltri et al., 2013) . (iii) After miRNA cleavage by DICER the 3 0 ends of several miRNAs get adenylated or uridylated. Koppers-Lalic et al. showed that miRNAs exhibiting an uridylated end are more abundant in extracellular vesicles while the proportion of adenylated miRNAs seems to be higher within the cell (Koppers-Lalic et al., 2014) . (iv) Main components of the miRNA induced silencing complex (miR-ISC) such as Ago2 and GW182 were not only found to co-localize with multivesicular bodies (Gibbings et al., 2009 ) but their presence was also confirmed within extracellular vesicles . (v) Intracellular transcript levels of targeted mRNAs were shown to impact on secretory levels of the corresponding miRNA (Squadrito et al., 2014) .
Upon release of extracellular vesicles (EV) from the producer cells, EVs were shown to transport their miRNA cargo in a protected way over short and long distances (Mitchell et al., 2008) in the blood stream and to deliver it to recipient cells (Squadrito et al., 2014) . In addition, miRNAs are still active after extravesicular transfer to the recipient cells where they inhibit their target transcripts and consequently alter the recipient's cellular behavior (Hergenreider et al., 2012; Mittelbrunn et al., 2011) . In particular 3 different mechanisms have been proposed on how EVs interact with and influence recipient cells: (i) EVs are taken up into recipient cells by endocytosis (Svensson et al., 2013; Tian et al., 2010) . (ii) EVs can fuse with the plasma membrane of the target cells (Montecalvo et al., 2012) , and (iii) EVs can interact with cell surface receptors resulting in an altered intracellular signaling (Th ery et al., 2009) .
In summary, it has been shown that selective packaging allows stable transport of miRNAs within the circulation and a potentially non-random uptake by target cells based on the type of packaging provided (F evrier and Raposo, 2004) . These findings have led to the hypothesis that circulating miRNAs might not only be surrogate biomarkers that reflect the physiology of the donor tissue, but could actually act in a hormone-like fashion on target cell behavior (Cortez et al., 2011) . Consequently, we have seen tremendous interest in circulating miRNAs as biomarkers for various diseases over the last years (De Guire et al., 2013) , but only a limited number of studies have tried to weigh potential advantages of circulating miRNAs against the challenges that must be faced to establish clinical utility.
3. Clinical utility of circulating microRNAs: strengths, weaknesses, opportunities and threats 3.1. How to define clinical utility?
In 2007, Morrow et al. published a list of criteria to benchmark the utility of novel cardiovascular biomarkers (Morrow and De Lemos, 2007) . These criteria were adopted for this review to evaluate the clinical utility of circulating miRNAs in bone diseases ( Fig. 2a): i) Measurability in a clinical setting: in order to be of clinical value, analytical tools at reasonable cost must be in place that allow to measure the biomarker in a timely manner producing accurate and reproducible results. The impact of potential pre-analytical influences on analyte detection (measurement conditions, sample handling) must have been evaluated and eventual preanalytical sources of error must be controllable. ii) Validation: in order to be clinically useful, thorough clinical validation of the biomarker in multiple studies is required in order to proof a strong and consistent association between the biomarker and the outcome or disease of interest, and to determine reference values and decision-limits. Ideally, validation studies include longitudinal population based studies that reflect the incidence of the disease or outcome. In addition, evidence should be collected demonstrating that the biomarker provides relevant clinical information beyond existing established tests. iii) Decision Support: it is moreover pivotal that the information provided by the novel biomarker directly impacts medical decision making, and is therefore clinically useful. This means that a test result must be linked to an actionable step, which for example may involve helping the physician to detect the disease at an early stage, to establish the diagnosis, to select the appropriate treatment or to monitor disease progression or therapy response.
How do circulating miRNAs match up to these benchmarks for performance?
In the following, an assessment of the potential utility of circulating miRNA as biomarkers for bone diseases both in respect to these general benchmarks as well as specific requirement for bone diseases is given (Fig. 2b) .
Strengths of circulating miRNAs as biomarkers
Measurability: Circulating microRNAs are a minimal or noninvasive source of biomarkers as they are contained in serum and plasma samples, urine, cerebrospinal fluid, and saliva allowing minimal-invasive detection and therefore a broad applicability in clinics and research repositories. This is especially advantageous for diseases affecting tissues that are not easily accessible for biopsies such as bone. Mitchell and others demonstrated that miRNA measurements in serum and plasma collected from the same healthy individuals from the same blood draw are highly correlated (Chen et al., 2008; Mitchell et al., 2008) . However, the choice of anticoagulant (Heparin, EDTA, sodium citrate or Natriumfluorid/potassium oxalat (NaF/KOx)) for plasma sample collection is important, since heparin interferes with enzyme activity in PCR-based assays (Boeckel et al., 2013; García et al., 2002) . Similar to heparin, also citrate exhibits an inhibitory effect on qPCR and both are therefore not recommended for miRNA quantitation by qPCR. Unlike heparin, EDTA is removable from the PCR mastermix and is therefore considered the anticoagulant of choice for PCRbased miRNA profiling . The use of NaF/KOx as anticoagulant resulted in increased miRNA detection rates and may be a suitable alternative if serum or EDTA blood is not at disposition (Kim et al., 2012) . The time to centrifugation as well as centrifugation speeds have been shown to critically impact the detection of miRNAs in EDTA plasma samples since it affects the contamination with platelet-derived miRNAs (Cheng et al., 2013) . In contrast, miRNA detection in serum was shown to be less sensitive towards pre-processing variations. Circulating microRNAs are robust analytes: once collected, circulating miRNAs exhibit remarkable stability in body fluids even after prolonged exposure (up to 24 h) to room temperature (Mitchell et al., 2008) , which is due to their encapsulation or association with proteins (see section 2.1. of this review). This makes their use advantageous in clinical routine and in an outpatient setting, where the time span between sampling and sample analysis can sometimes vary due to unforeseen delays. The same is true for large multicenter trials with central laboratory services where processing times from sample collection to sample analysis can go up to 24 h (Gonz alez- Gross et al., 2008) . Other extreme conditions such as exposure to low and high pH solutions, repeated freeze and thaw cycles do not compromise miRNA stability in serum (Chen et al., 2008) . Given the continuously rising number of newly detected miRNAs and given the limited number of miRNAs that were tested for their stability in the aforementioned experiments it is nevertheless generally advisable to minimize pre-analytical deviations from established sample handling standards (Cheng et al., 2013) . If samples are stored properly at low temperature (i.e. below À70 C) this allows to obtain high quality data from retrospective analyses of longitudinal studies, where samples likely have been stored over decades . This is extremely helpful as it reduces the cost and timelines for biomarker development for chronic diseases such as musculoskeletal diseases, which develop over years. Polymerase chain reaction serves as reliable tool in molecular diagnostics: Another advantage for using circulating miRNAs as biomarkers is that reverse-transcription quantitative PCR (qPCR) is a well-established molecular diagnostic technique, with several examples of successful clinical applications (Bernard and Wittwer, 2002; Murphy and Bustin, 2009; Sandvik et al., 2006) and available guidelines for how to standardize the reporting of qPCR data . While PCR seems to be the gold standard method, especially next-generation sequencing (Williams et al., 2013) , targeted miRNA-sequencing (Bourzac et al., 2011) or other hybridization-and ligationbased techniques have been developed (Zuo et al., 2015) , which performed adequately in a recent quality control study (Mestdagh et al., 2014) . Finally, certain applications of circulating miRNAs will require rapid turnaround of the test results, which is why solutions for point-of-care devices for miRNA analysis have already been reported (Campuzano et al., 2014) .
Weaknesses of circulating miRNAs as biomarkers
Lifestyle and disease cause inter-individual variation in circulation miRNA levels: While pre-analytical effects can be managed, several studies have described changes in circulating miRNAs levels as a consequence of lifestyle habits, circadianrhythm or comorbidities, which might limit the clinical utility of circulating miRNAs as biomarkers. While gender is so far not believed to be a major driver of variation in circulating miRNA levels (Chen et al., 2008) , it was shown that physical activity (Baggish et al., 2011) , smoking habits (Takahashi et al., 2013) , diet (through diet-derived miRNAs or modulation of HDL lipoprotein, a known circulation miRNA carrier, Witwer, 2012) , and presumably circadian rhythm (Shende et al., 2011) could influence the levels of specific circulating miRNAs. In addition, it has been reported that the overall content of miRNAs in the circulation is lowered in patients with chronic kidney disease (Neal As a consequence, biomarker studies focusing on circulating miRNAs require a strict definition of patient inclusion and exclusion criteria that address these factors, in order to minimize the number of confounding factors that add noise to the data. Hence, biomarker discovery could be improved by including only patients with an estimated glomerular filtration rate (eGFR) ! 30 ml/min/1.73 m 2 ,
and to restrict the analysis to samples that were taken in the morning after overnight fasting. Following the identification and initial validation of a promising biomarker (or combination of markers, i.e. signature), it is pivotal to systematically evaluate its sensitivity against pre-analytical as well as lifestyle factors in order to define a robust pre-analytical protocol for subsequent clinical utility studies.
Analytical standardization: a recent comparative study of several PCR-platforms and next-generation sequencing for the quantification of cellular and circulating miRNAs reported surprisingly low concordance between miRNAs that were called differentially expressed by each platform (Mestdagh et al., 2014) . This suggests that analytical platforms and protocols must be frozen during entire biomarker development (i.e. discovery and validation), and that the migration of the final biomarker to a commercial diagnostic platform likely requires additional efforts for technical and clinical validation.
In addition, most miRNA expression data in biofluids are relative expression values rather than absolute counts per volume, which affects the comparability of data sets between different labs and potentially even between studies in the same lab. Consequently, many studies have applied data normalization prior to statistical analysis. However, there is no consensus over whether bona fide reference genes, global mean normalization or other approaches perform best. And most likely, there is no "best" universally applicable normalization strategy, since this choice is highly depended on the number of miRNAs, the number of samples analyzed, as well as the technology platform and its technical variation. For that purpose it is highly recommended to conduct a thorough characterization of the technology platform and its variance before using it for biomarker discovery. In qPCR experiments, this can be achieved by using spike-in controls at each step during the entire workflow, i.e. RNA extraction, cDNA synthesis and PCR amplification. In addition, the impact of normalization on the outcome should be assessed. In our experience, if a robust analytical protocol has been implemented and the efficiencies and variance of each handling step is monitored, it might not be necessary at all to normalize relative circulating miRNA expression data.
Opportunities for circulating miRNAs as biomarkers
Tissue specific miRNAs are present in the circulation: the fact that certain miRNAs are only expressed in a specific type of cell or tissue allows to draw conclusion about tissue physiology by monitoring serum/plasma levels of these miRNAs. In case of mild cognitive impairment and Alzheimer's disease, the analysis of brain-specific miRNAs has been shown to correlate with cognitive function and to be of utility for diagnosis, prognosis and monitoring of cognitive impairment (Sheinerman et al., 2012 (Sheinerman et al., , 2012 . A different application was reported by Rosenfeld et al. in 2008 , who used expression information from 48 miRNAs to accurately identify the tissue type of cancers with unknown primary origin (Rosenfeld et al., 2008) . Later on this test was improved to incorporate 64 miRNAs, which allowed highly accurate classification of 42 different tumor types (Meiri et al., 2012) , and is now commercially available. A use case of circulating tissue-specific miRNAs is as sensitive and minimal invasive markers of organ-related diseases or tissue injury (Enache et al., 2014; Laterza et al., 2009) , which might in the future complement or even replace other biomarkers. Pathway-specific miRNAs with strong link to the disease pathology: ubiquitously expressed miRNAs that are strongly associated with certain cellular processes are useful markers of pathology, as shown in case of miR-21-5p, which has been found to be strongly linked to the proliferative and anti-apoptotic characteristic of a cell (Xu et al., 2014) , miR-31-5p that is involved in the regulation of several steps during bone formation or miR-126-3p, which is an endothelial miRNAs with wellcharacterized functions during vascular inflammation and biomarker of cardiovascular and metabolic diseases (Zampetaki et al., , 2010 . Overall, the combined analysis of both tissue-specific and ubiquitous, phenotype-related miRNAs from liquid biopsies holds great promise to identify highly specific and sensitive biomarkers for various diseases. This is in part be confirmed by encouraging data from discovery and validation studies of circulating miRNAs in the context of diagnosing several oncological as well as non-oncological disease (De Guire et al., 2013) .
Threats and challenges for circulating miRNAs as biomarkers
Clinical validation: as with other types of biomarkers, the validation of circulating microRNAs can be challenging. First of all, study designs need to pay attention to preanalytical influences, which need to be standardized in order to minimize technical variance between studies. Second, although the transcription of most miRNAs is strongly linked to biological processes and specific cellular phenotypes, similar phenotypes are affected and altered during numerous pathophysiological events. Therefore, the information about deregulation of a single miRNA (e.g. as consequence of increased proliferation), might lack the required specificity to the disease of interest. A solution to this challenge could be the use of miRNA combinations rather than individual miRNAs as disease biomarkers, and of course the conduction of elaborate clinical validations. Reference levels: a second challenge derives from a large heterogeneity between studies, since there are no standardized pre-analytical and analytical protocols published and followed by research labs. In addition, various technology platforms as well as approaches to data analysis impact the data and comparability between labs. This leads to the fact that for example in case of human serum or plasma, no reference values for miRNA levels in healthy populations have yet been established, making it very difficult to compare results across various studies. Consequently, the adoption of circulating miRNA biomarkers in the clinics require urgently the implementation of reference values and methods, for example through the development of analytical kits that are specifically designed and validated for the analysis of a selection of circulating miRNAs. Cost effectiveness: lastly, it is clear that (in the beginning) the cost of laboratory developed miRNAs tests or IVD kits will not be competitive to high volume protein-based tests. Compared to infectious disease diagnostics, where completely automated solutions for DNA extraction and PCR detection have substantially lowered cost (Rouet et al., 2005) , this infrastructure has not yet been developed for circulating miRNAs. Therefore, it can be anticipated that initial clinical applications of circulating miRNAs will be confined to areas with medium to low turnover and/or limited competition. However, with the expiry of patents related to PCR and RNAi and the development of automated analytical technologies, circulating miRNAs might become valuable and competitive diagnostics in high volume indications.
Circulating microRNAs as biomarkers for bone diseases e focus osteoporosis

MicroRNAs with roles in bone disease
The importance of miRNAs in controlling bone homeostasis and metabolism is more and more recognized. Numerous studies have elaborated on the regulation of miRNA expression during osteoblast and osteoclast formation (Bakhshandeh et al., 2012; Eguchi et al., 2013) , and carefully characterized the variance of miRNA expression in primary bone cells (Laxman et al., 2015) . Other studies have reported phenotypic effects on bone cells after substitution/knockdown of selected miRNAs using in vitro model systems and in some instances reported putative target genes . Finally, it has been shown that bone-active hormones such as RANKL (Kagiya and Nakamura, 2013) , estrogen (Sugatani and Hruska, 2013) , or bonemorphogenic protein (BMP) , impact intracellular miRNA transcription in vitro.
As a skeletal disease of perturbed bone formation and resorption, osteoporosis is centered within this context: it is characterized by excessive bone resorption and defective bone formation leading to bone loss and compromised microarchitecture that are associated with an increased risk of bone fracture (Raisz, 2005) . Two studies have addressed miRNA expression in osteoporotic bone tissue. One study used an ovariectomized mouse model to investigate changes in miRNA and mRNA levels four weeks after surgery . They reported significant effects for 9 miRNAs. Integration of miRNA data with putative mRNA target data revealed that CREB and PPARg might be modulated by these miRNAs. Finally, miR-127 and miR-136, which were induced after ovariectomy, also affected osteogenic differentiation in vitro. The second study described the human miRNome in bone tissue (trabecular component of femoral heads) of osteoporotic versus osteoarthritic patients (Garmilla-Ezquerra et al., 2014; Hu et al., 2011) . Initially bone biopsies of 8 cases and controls were studied by RT-qPCR arrays to identify 13 potential candidates, which did, however, not overlap with miRNAs reported in OVX mice. After replication in 36 individuals (n ¼ 18 per group), significant up-regulation of miR518f and down-regulation of miR-187 in osteoporotic bone was reported.
To this point, few studies have also addressed the therapeutic utility of miRNAs in vivo using different animal models. In 2009, Li et al. were the first to report that the mature miR-2861 expression was absent in bone specimens of two related adolescents with primary osteoporosis due to a homozygous mutation in the precursor miRNA sequence (Li et al., 2009) . Upon further investigation they found that wildtype miR-2861 supports BMP-2 induced osteoblastogenesis through silencing of HDAC5, which in turn increases RUNX2 expression. In vivo, silencing of miR-2861 using antagomirs, single-stranded chemically engineered anti-sense oligonucleotides (Krützfeldt et al., 2005) , inhibited bone formation. In 2013, Wang et al. reported elevated expression of miR-214-3p in bone of aged male and female subjects, which correlated with a decreased rate of bone formation . Upon silencing the activity of miR-214-3p in vivo by delivering antagomir oligonucleotides increased osteoblast formation was observed in a mouse ovariectomy model. Another promising therapeutic target for osteoporosis or osteosarcoma could be miR-34a, which was shown to block osteoclastogenesis using transgenic and knockout mouse models (Krzeszinski et al., 2014) . Krzeszinski et al. showed that chitosan nanoparticle-based delivery of synthetic miR-34a to mice with ovariectomy-induced osteoporosis enhance bone volume and trabecular number and thickness as well as cortical bone volume (Krzeszinski et al., 2014) . Finally, miR-31-5p was found to regulate the expression of various transcription factors during osteoblast differentiation thereby decelerating osteogenesis in vitro (Deng et al., 2013) . By using an in vivo model for critical-sized defects in rats, it was shown that knockdown of miR-31 in bone marrow stromal stem cells prior to their delivery to bone defects, significantly improved bone tissue repair (Deng et al., 2014) .
Circulating microRNAs in osteoporosis
The role of microRNAs as biomarkers for bone diseases has not been given much attention until recently. However, given the fact that osteoblasts seem to communicate via shuttling of exosomes (Deng et al., 2015) , and based on the finding that the exosomal miRNA content is changing during osteoblastogenesis (Xu et al., 2014) , supports the hypothesis to use extracellular miRNAs as biomarkers of bone metabolism.
The first attempt to characterize miRNAs associated with discordant BMD status was focused on measuring miRNAs in circulating monocytes. Circulating monocytes are relevant to bone homeostasis since they can become activated to differentiate into osteoclasts and to secrete osteoclastogenic factors such as interleukins and TNF-a. Wang and colleagues analyzed miRNA expression in human circulating blood monocytes in a small cohort of 20 postmenopausal Caucasian females . These women had either a high bone mineral density (n ¼ 10, mean spinal BMD by DXA 1.13 ± 0.06 g/cm 2 ) or low bone mineral density (n ¼ 10, mean spinal BMD 0.83 ± 0.07 g/cm 2 ). Of the 365 miRNAs screened, miR-133a expression survived qPCR validation and was found to be expressed in significantly higher levels in women with low BMD than in women with high BMD. However, in circulating Bcells, which were derived from the same study, miR-133a levels were similarly expressed irrespective of BMD. These findings suggested a limited, monocyte specific role of miR-133a in the setting of postmenopausal osteoporosis. In 2014, Li et al. replicated the upregulation of miR-133a in the cell-free plasma samples of osteoporotic versus osteopenic women in a Chinese cohort of 120 postmenopausal women (Li et al., 2014) . Besides miR-133a, Li et al. also found miR-21-5p to be downregulated in osteoporotic women establishing both miRNAs as potential biomarkers for postmenopausal osteoporosis. Interestingly, miR-146a-5p, to which an inhibitory effect on osteoclastogenesis in vitro was attributed (Nakasa et al., 2011) , did not exhibit differential expression between osteoporotic and osteopenic groups (Li et al., 2014) . Correlations between plasma levels of circulating miR-21-5p, miR-133a and miR-146a-5p and spinal and hip BMD by DXA were also reported. While miR-146a-5p was not significantly correlated with DXA BMD values, both miR-21-5p and miR-133a showed moderate to strong significant correlations with BMD in all three subcohorts (normal BMD, osteopenic and osteoporotic women) (correlation coefficients ranging from 0.46 to 0.62).
By utilizing the miRNA qPCR-array dataset on monocytes in women with high and low BMD by Wang et al. , Cao et al. (Cao et al., 2014) further investigated four miRNAs (miR27b-3p, miR-422a, miR-151-3p, and miR-152-3p ) that had demonstrated a slight differential expression between low and high BMD women in the previous study. Technical validation by qPCR revealed that miR-422a was significantly upregulated in the low BMD group compared to the high BMD group.
Seeliger et al. compared serum miRNA expression against bone tissue expression in samples from patients with acute osteoporotic using non-osteoporotic fractures as controls (Seeliger et al., 2014) . They initially screened 83 miRNAs in serum samples of patients with acute osteoporotic fractures and identified 9 miRNAs (miR-21-5p, miR-23a-3p, miR-24-3p, miR-93-5p, miR-100-5p, miR-122a, miR-124-3p, miR-125b-5p and miR-148a-3p) to be differentially expressed in serum biopsies of patients with osteoporotic compared to non-osteoporotic fractures, of which miR-21-5p, miR23a-3p, miR-24-3p, miR-100-5p and miR-125b-5p were also found upregulated in bone tissue biopsies. Weilner et al. searched for serum miRNAs in patients with recent osteoporotic and agematched healthy control subjects (Weilner et al., 2015) . By introducing quality standards for qPCR screening using spike-in controls as well as present-value and hemolysis thresholds, they reported 10 miRNAs that were highly regulated in patients with osteoporotic fractures including let-7g-5p, miR-10b-5p, miR-133b, miR-22-3p, and miR-328-3p. By testing the osteoblastogenic activity of these miRNAs as well as miRNAs reported by Seeliger et al. in vitro, it was shown that the majority of miRNAs that show serum level changes in response to osteoporotic fractures can modulate osteogenic differentiation of mesenchymal stem cells, suggesting a causal relationship between the miRNA biomarkers and the osteoblast differentiation based arm of the disease. Overall, let-7g-5p, miR10b-5p, miR-100-5p, miR-148a-3p, and miR-21-5p were found to impact osteogenesis. Interestingly, miR-148a-3p and miR-21-5p are also known to be involved in the regulation of osteoclastogenesis (Cheng et al., 2013; Sugatani and Hruska, 2013) . These results strongly encourage the development and further cross validation of cell free blood-based miRNAs with bone miRNAs. Two other studies have assessed the changes in miRNA expression in response to osteoporotic fractures: a Spanish cohort including a group of osteoporotic patients with prevalent fractures and a control group of osteoarthritic patients without fractures and normal BMD values (Panach et al., 2015) . In the discovery study, 179 miRNAs were analyzed in pooled samples to find that 12 miRNAs were differentially regulated in serum. The analysis of these miRNAs was replicated in 12 additional controls and 15 cases and confirmed significant up-regulation for miR-122-5p, miR-125b-5p, and miR-21-5p, which had also been reported by Seeliger and partially by Weilner (Seeliger et al., 2014; Weilner et al., 2015) . In order to identify additional miRNA biomarkers for osteoporosis Meng et al. recently screened the expression profile of 331 miRNAs in whole blood samples of 48 postmenopausal Chinese women who were stratified according to their BMD-values (Meng et al., 2015) . Unadjusted comparison of miRNA expression between the pooled osteoporotic (n ¼ 25) and osteopenic cohorts (n ¼ 23) revealed six miRNAs (miR-130b-3p, -151a-3p, -151b, -194-5p, -590-5p, and -660-5p ) that were significantly upregulated in the blood of participants with osteoporosis relative to those with osteopenia. External validation in 24 additional post-menopausal women confirmed the significant increase in expression for all five miRNAs (miR-130b-3p, -151a-3p, -151b, -194-5p, -590-5p ) except miR-660-5p. Interestingly, high miRNA expression levels of miR-130b-3p, -151a-3p, -151b, -194-5p were found significantly correlated with low bone mineral density levels as assessed by spinal and femoral neck T-scores with miR-194-5p and miR-151b showing the greatest promise as biomarker with significant correlation coefficients of between 0.75 and 0.83. However, this study has several limitations that have to be taken into account when interpreting the results: clinical correlations between miRNA expression and T-scores were based on a very limited number of observations, the study used pooled samples and also did not collect any information on fracture history.
In summary, several studies have reported miRNA expression in bone tissue biopsies and liquid biopsies in human subjects in the context of osteoporosis (Table 1) . Due to the diverse nature of study designs, the number and type of regulated miRNAs identified varies significantly. Important findings include that bone and serum expression patterns seem to be correlated for some miRNAs (Seeliger et al., 2014) , and that a significant fraction of miRNAs that were found regulated in serum of patients with osteoporotic fractures exhibit positive or negative osteogenic activity (Weilner et al., 2015) . This suggests, that perturbations in circulating miRNA levels in patients with osteoporosis might be directly linked to altered bone metabolism.
Circulating microRNAs e complex biomarkers for multifactorial diseases?
The studies summarized in Table 1 provide evidence that specific circulating miRNA levels change in individuals with musculoskeletal conditions and are correlated to skeletal parameters such as bone mineral density. Nevertheless, the biological interpretation of circulating miRNA data is challenging, since the majority of miRNAs is not tissue specific and hence their origin in cell-free blood cannot be defined. It is assumed that a significant fraction of circulating miRNAs is derived from the main cellular blood components, i.e. erythrocytes and platelets (Willeit et al., 2013) . It has further been shown that different blood cell types exhibit distinct miRNA expression profiles (Leidinger et al., 2014) . This also includes CD14 þ monocytes, the precursor-cells of osteoclasts, which were found to be the only blood cells with detectable levels of miR-326, miR-378* and miR-502-5p. In addition, several other miRNAs can be found in the literature, which are either enriched or depleted in CD14 þ cells compared to other blood cells (Leidinger et al., 2014) . Interestingly, among these miRNAs are miR-155-5p and miR-31-5p, which have been previously reported to impact osteoclast formation (Mizoguchi et al., 2013; Zhang et al., 2012) . Besides blood cells also other tissues are known to shed their miRNA contents into the blood: i) endothelial cell enriched miRNAs (e.g. miR-126-3p) show good detectability in cell-free blood and were shown to be predictive of cardiovascular events in the Bruneck study (Zampetaki et al., , 2010 . ii) Liver-specific miR-122 is highly abundant in serum and plasma. iii) Brain-enriched miRNAs are detectable in plasma and elevated during the onset of neurodegenerative diseases (Sheinerman et al., 2012) . iv) Several myoblast specific miRNAs have been reported (Kornfeld and Brüning, 2012; McCarthy, 2008) , and shown to be released from muscle tissue and highly up-regulated following muscle injuries such as myocardial infarction (Fichtlscherer et al., 2010) .
This shows that the cell-free miRNA content in human blood is complex, since it originates from various cell types in different tissues. However, there is also a general consensus that musculoskeletal diseases like osteoporosis are complex, because fracture risk is a combination of skeletal risk factors affecting bone strength and extra-skeletal risk factors, such as muscle strength, balance and vision, which increase the risk of falling. Consequently, it could be argued that the pathophysiological processes that lead to increased risk of fractures not only take place in bone but also in other tissues interacting with bone (see Fig. 3 ). Blood circulating microRNAs that are secreted from various cell types and tissues, might therefore present a readout that could capture this complexity. In the following section potential overlaps in circulating miRNA signatures for osteoporosis with signatures for muscle strength/weakness and aging will be discussed.
Cross-links to sarcopenia
Muscle weakness is highly relevant to bone physiology and the risk of sustaining (osteoporotic) fractures (Be'ery-Lipperman and Gefen, 2005) . It is of note that miR-133a/b, which were observed to change in cell-free blood during three independent miRNA studies in osteoporosis (Table 1) , is strongly induced in cardiac and skeletal muscle during development (Chen et al., 2006) . The transcription of miR-133a/b is known to be controlled by muscle-associated transcription factors and gives rise to polycistrons that contain two other miRNAs, miR-1 and miR-206 (Townley-Tilson et al., 2010) . These "myomiRs" have been shown to impact myoblast proliferation and differentiation through feedback loops with muscle associated transcription factors (SRF and MyoD), and therefore act as important regulators of muscle homeostasis (Chen et al., 2006) . Two studies on subjects with healthy muscle have reported changes in intracellular levels of myomiRs in response to acute (60 min) as well as long-term exercise for 6 up to 12 weeks (Keller et al., 2011; Nielsen et al., 2014) . In addition, recent studies have also reported changes in circulating miRNAs levels following exercise of young healthy subjects (Zacharewicz et al., 2013) , which found that miR-133b is upregulated in plasma of trained individuals following acute exercises. Interestingly, also miR-126 that is highly expressed in the endothelium was found up-regulated in plasma in individuals undergoing acute exercise, which might reflect increased blood circulating and endothelial stress or even injury (Uhlemann et al., 2014) . In aged skeletal muscle compared to young muscle, a significant up-regulation of myomiRs (except miR-206) was observed (Drummond et al., 2011) . Following exercise and protein intake, it was further found that only the muscle of young individuals reacted to the stimulus by down-regulation of miR-1 while miRNA expression in muscle of aged individuals did not change (Drummond et al., 2011) .
In the light of these data it seems likely that miRNAs impact muscle homeostasis, and that changes that occur during aging could contribute to the pathophysiology of muscle wasting causing sarcopenia. Brown and Goljanek-Whysall recently discussed in detail how specific miRNAs could contribute to the pathophysiology during sarcopenia (Brown and Goljanek-Whysall, 2015) . However, to this stage no data on circulating miRNAs in sarcopenia have been released. Therefore, the question in how far circulating miRNA signatures of sarcopenia overlap with osteoporosis cannot be answered.
Cross-link to aging
Aging affects several body tissues, and is well known to negatively impact the physiology of cells, tissues and organs, resulting in reduced functionality and ability to regenerate. Since the observation in murine parabiosis models, that connecting the circulation of old animals with young animals can improve the regenerative potential of old mouse tissues (Conboy et al., 2005) , circulating factors have been deemed important contributors to the "aging" phenotype. Consequently, in recent years circulating miRNAs have been thoroughly studied in the context of aging, including the Ames dwarf mice, which have a deficiency in three pituitary hormones (growth hormone (GH), prolactin, and thyrotropin) that causes a 70% increase in lifespan. By analyzing circulating miRNAs in Ames dwarf mice and wild-type controls it could be shown that specific miRNAs are highly regulated in aged mice but remain unchanged in long-lived mice (Victoria et al., 2015) . This miRNA signature of "genotype-by-age" was predicted to be associated with 5 biological processes, including "Ca 2þ modulating WNT receptor signaling pathway" (Victoria et al., 2015) , a potential link between aging and proliferation/cancer or bone homeostasis. In humans, an exploratory study analyzed 365 circulating miRNAs in young and aged individuals as well as centenarians (Olivieri et al., 2012) , and identified three general patterns for circulating miRNAs in young, aged, and long-aged individuals. Analysis of miR-21-5p was replicated in an independent group of samples, to show that its levels are increased in octogenarians compared to young individuals but also centenarians (Olivieri et al., 2012) . Based on predicted involvement of miR-21-5p with TGFb signaling and correlation to other circulating inflammatory markers, miR-21-5p was proposed as "inflamma-miR" that might reflect the systemic inflammatory status (Olivieri et al., 2013) . Besides inflammatory processes that contribute to changes in the aged circulating, also the senescence associated secretory phenotype (SASP) of different cell types is likely to be reflected in circulating miRNAs (Weilner et al., 2013) . In senescent bone-marrow derived mesenchymal stem cells it was observed that the majority of miRNAs is up-regulated, with the exception of miR-199b-5p that is downregulated, thus increasing the translation of its target LAMC1, which encodes laminin proteins required for cell adhesion and migration as well as signal transduction (Yoo et al., 2014) . Downregulation of miR-199b-5p in bone tissue in vivo was recently shown on the basis of comparing miRNA expression in three aged (18-month) versus three young (3-month) mice . In contrast, miR-188-5p was highly induced in bone tissue of aged mice, a finding that could also be replicated in bone marrow stem cells of male and female human donors. Homozygous miR-188 À/À knockout mice exhibited higher bone mass with age as well as less fat accumulation in the marrow. This was the consequence of a switch between osteogenic and adipogenic differentiation caused by elevated miR-188-5p levels with age. This was shown to be mediated by two direct targets of miR-188-5p, RICTOR and HDAC9, thus affecting PPARg as well as mTOR function . Although neither circulating miR-199b-5p nor miR-188-5p have so far been described in the context of osteoporosis, this is likely due to the fact, that they were not included in the analysis of current studies.
Conclusions and outlook
At this point, there is some evidence that bone physiology as well as the onset, progression and manifestation (i.e. fracture) of age-related musculo-skeletal diseases might be reflected in changes in circulating miRNA levels. However, clinical utility of circulating miRNAs in musculo-skeletal diseases has not been established, because so far the study designs were not suited to identify such miRNAs that can give a prognosis for future risk of fractures, or predictive of a treatment response. In order to answer these questions, a systematic biomarker development program needs to be conducted, which does not exclude miRNA a priori but starts by analyzing the full miRNome. Pre-selected candidates should then be included in the analysis of prospective studies with follow-up for fracture incidence after 5e10 years. Finally, similar to other bone turnover markers, population based studies will be required to determine reference values and thresholds and to decide over the clinical utility of microRNAs in the management of musculo-skeletal disease. However, the tissue and pathology specific patterns of circulating miRNAs does strongly suggest that the analysis of multiple miRNAs as complex signatures in serum or plasma will evolve into an important biomarker for prognosis, diagnosis, patient stratification, down to personalized medicine approaches.
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